+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Systemic Lupus Erythematosus - Pipeline Review, H2 2019

  • ID: 4901399
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 642 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Bio-Path Holdings Inc
  • Exinda Therapeutics LLC
  • Immplacate
  • Kyowa Kirin Co Ltd
  • Ra Pharmaceuticals Inc
  • MORE
Systemic Lupus Erythematosus - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H2 2019, provides an overview of the Systemic Lupus Erythematosus (Immunology) pipeline landscape.

Systemic lupus erythematosus (SLE) is an autoimmune disease that causes a chronic inflammatory condition. The inflammation triggered by SLE affect many organs in the body, including skin, joints, kidneys, brain, and other organs. Several factors have been associated with the disease such as genetics, environment and gender and hormones. Symptoms can vary and can change over time. Common symptoms include severe fatigue, painful or swollen joints, headaches, rash on cheeks and nose called butterfly rash, hair loss and anemia.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Lupus Erythematosus (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 10, 35, 21, 63, 15 and 2 respectively. Similarly, the Universities portfolio in Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 1, 11 and 1 molecule, respectively.

Systemic Lupus Erythematosus (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Systemic Lupus Erythematosus (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Systemic Lupus Erythematosus (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Systemic Lupus Erythematosus (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Lupus Erythematosus (Immunology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Systemic Lupus Erythematosus (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Bio-Path Holdings Inc
  • Exinda Therapeutics LLC
  • Immplacate
  • Kyowa Kirin Co Ltd
  • Ra Pharmaceuticals Inc
  • MORE
Introduction
Systemic Lupus Erythematosus - Overview
Systemic Lupus Erythematosus - Therapeutics Development
Systemic Lupus Erythematosus - Therapeutics Assessment
Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development
Systemic Lupus Erythematosus - Drug Profiles
Systemic Lupus Erythematosus - Dormant Projects
Systemic Lupus Erythematosus - Discontinued Products
Systemic Lupus Erythematosus - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Systemic Lupus Erythematosus, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Systemic Lupus Erythematosus - Pipeline by AbbVie Inc, H2 2019
Systemic Lupus Erythematosus - Pipeline by ACEA Therapeutics Inc, H2 2019
Systemic Lupus Erythematosus - Pipeline by Alpine Immune Sciences Inc, H2 2019
Systemic Lupus Erythematosus - Pipeline by Aluda Pharmaceuticals Inc, H2 2019
Systemic Lupus Erythematosus - Pipeline by Amgen Inc, H2 2019
Systemic Lupus Erythematosus - Pipeline by Apellis Pharmaceuticals Inc, H2 2019
Systemic Lupus Erythematosus - Pipeline by Apimeds Inc, H2 2019
Systemic Lupus Erythematosus - Pipeline by APT Therapeutics Inc, H2 2019
Systemic Lupus Erythematosus - Pipeline by Araim Pharmaceuticals Inc, H2 2019

List of Figures
Number of Products under Development for Systemic Lupus Erythematosus, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AbbVie Inc
  • ACEA Therapeutics Inc
  • Alpine Immune Sciences Inc
  • Aluda Pharmaceuticals Inc
  • Amgen Inc
  • Apellis Pharmaceuticals Inc
  • Apimeds Inc
  • APT Therapeutics Inc
  • Araim Pharmaceuticals Inc
  • Asahi Kasei Pharma Corp
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Atlantic Bio Sci LLC
  • Aurinia Pharmaceuticals Inc
  • BellBrook Labs LLC
  • Bio-Path Holdings Inc
  • Biocon Ltd
  • Biogen Inc
  • Biotest AG
  • Boehringer Ingelheim International GmbH
  • Boston Pharmaceuticals Inc
  • Bristol-Myers Squibb Co
  • Capricor Therapeutics Inc
  • Carna Biosciences Inc
  • Cells for Cells SA
  • Chong Kun Dang Pharmaceutical Corp
  • Citryll BV
  • Corbus Pharmaceuticals Inc
  • Corestem Inc
  • CuraVac Inc
  • Cyteir Therapeutics Inc
  • Daewoong Pharmaceutical Co Ltd
  • Domainex Ltd
  • Eli Lilly and Co
  • Epsilon-3 Bio Ltd
  • Ergon Pharmaceuticals LLC
  • Exinda Therapeutics LLC
  • F. Hoffmann-La Roche Ltd
  • Galapagos NV
  • Genentech Inc
  • GeneScience Pharmaceuticals Co Ltd
  • Genosco Inc
  • Genovax Srl
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Good T Cells Inc
  • HanAll Biopharma Co Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • HemoGenyx LLC
  • Ichnos Sciences Inc
  • Idorsia Pharmaceutical Ltd
  • IL-2Rx Inc
  • Iltoo Pharma
  • Immplacate
  • Immune Modulation Inc
  • Immungenetics AG
  • Immunomedics Inc
  • ImmunoQure AG
  • Immunwork Inc
  • Immupharma Plc
  • InnoCare Pharma Ltd
  • Innovimmune Biotherapeutics Inc
  • iSD Immunotech ApS
  • Janus Biotherapeutics Inc
  • JiangSu Qyuns Therapeutics Co Ltd
  • Johnson & Johnson
  • K-Stemcell Co Ltd
  • Kangpu Biopharmaceuticals Ltd
  • Karyopharm Therapeutics Inc
  • Kezar Life Sciences Inc
  • Kine Sciences
  • Kyowa Kirin Co Ltd
  • Landos Biopharma Inc
  • Lead Discovery Center GmbH
  • MedAnnex Ltd
  • MENTRIK Biotech LLC
  • Merck & Co Inc
  • Merck KGaA
  • Millennium Pharmaceuticals Inc
  • MorphoSys AG
  • Mount Tam Biotechnologies Inc
  • Nektar Therapeutics
  • Neovacs SA
  • Novartis AG
  • Omeros Corp
  • Pfizer Inc
  • Pharchoice Therapeutics Inc
  • ProNoxis AB
  • Provention Bio Inc
  • Ra Pharmaceuticals Inc
  • ReAlta Life Sciences Inc
  • RedHill Biopharma Ltd
  • Regen BioPharma Inc
  • RemeGen Ltd
  • Resolve Therapeutics LLC
  • Rheos Medicines Inc
  • Sanofi
  • Sareum Holdings Plc
  • SBI Biotech Co Ltd
  • Sengenics International Pte Ltd
  • Shanghai GeneChem Co Ltd
  • Shanghai Junshi Bioscience Co Ltd
  • SinoMab Bioscience Ltd
  • Suzhou Sinovent Pharmaceuticals Co Ltd
  • SynAct Pharma AB
  • Taiho Pharmaceutical Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Tonix Pharmaceuticals Holding Corp
  • UCB SA
  • Viela Bio Inc
  • Visterra Inc
  • Voronoi
  • Xencor Inc
  • XTL Biopharmaceuticals Ltd
  • ZyVersa Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll